News

Filter

Current filters:

ActelionPharmaceutical

1 to 9 of 30 results

Actelion submits selexipag for EMA marketing authorization in PAH

Actelion submits selexipag for EMA marketing authorization in PAH

03-12-2014

Swiss biotech firm Actelion has submitted a centralized Marketing Authorization Application to the European…

ActelionCardio-vascularEuropePharmaceuticalRegulationselexipag

PatientsLikeMe and Actelion to collaborate on new tool for non-Hodgkin’s lymphoma patients

PatientsLikeMe and Actelion to collaborate on new tool for non-Hodgkin’s lymphoma patients

06-08-2014

Swiss biotech firm Actelion is to partner with patient-powered research network PatientsLikeMe to create…

ActelionMitchell NagaoOncologyPatientsLikeMePharmaceuticalResearchSwitzerland

Actelion receives Health Canada approval of Opsumit for PAH

Actelion receives Health Canada approval of Opsumit for PAH

13-11-2013

Swiss biotech firm Actelion (SIX: ATLN) says that Canada’s regulator Health Canada has approved its…

ActelionCanadaCardio-vascularNorth AmericaOpsumitPharmaceuticalRegulation

Actelion says PAH drug Opsumit now available in USA

Actelion says PAH drug Opsumit now available in USA

05-11-2013

Actelion has confirmed that Opsumit 10mg, an oral, dual endothelin receptor antagonist for pulmonary…

ActelionMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonary

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

Actelion to start Phase III studies into cadazolid for C. difficile related diarrhea

11-09-2013

Swiss biotech firm Actelion (SIX: ATLN) will initiate a Phase III clinical development program to assess…

ActelionAntibiotics and Infectious diseasescadazolidEuropePharmaceuticalResearchVancomycin

Actelion's Opsumit for PAH shows reduction in morbidity and mortality

10-09-2013

Swiss biotech firm Actelion (SIX: ATLN) has announced key morbidity and mortality data in pulmonary arterial…

ActelionOpsumitPharmaceuticalResearch

Further highlights from European Society of Cardiology meeting

03-09-2013

The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

1 to 9 of 30 results

COMPANY SPOTLIGHT

Menarini

Back to top